1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
The Pathway to Prevention (P2P) for ME/CFS: A Dangerous Process
Gabby Klein gives an overview of the P2P process, shedding light on the pitfalls with advice as to what we can do in protest ...
Discuss the article on the Forums.

XMRV Infection in Patients With Prostate Cancer: Petrosa et al Apr 5 '10

Discussion in 'XMRV Research and Replication Studies' started by shrewsbury, Apr 5, 2010.

  1. shrewsbury

    shrewsbury member

    Messages:
    1,540
    Likes:
    55
    Urology Volume 75, Issue 4, April 2010, Pages 755-761
    doi:10.1016/j.urology.2010.01.038 | How to Cite or Link Using DOI
    Copyright 2010 Published by Elsevier Inc.
    Permissions & Reprints

    Cancer

    XMRV Infection in Patients With Prostate Cancer: Novel Serologic Assay and Correlation With PCR and FISH

    Rebecca S. Arnolda, b, Natalia V. Makarovac, Adeboye O. Osunkoyaa, b, d, Suganthi Suppiahd, Takara A. Scotta, Nicole A. Johnsona, Sushma M. Bhosled, Dennis Liottae, Eric Hunterc, d, Fray F. Marshalla, Hinh Lyd, Ross J. Molinarod, Jerry L. Blackwellc, f and John A. Petrosa, b, d, Corresponding Author Contact Information, E-mail The Corresponding Author

    a Department of Urology, Emory University School of Medicine, Atlanta, Georgia

    b Atlanta Veterans Affairs Medical Center, Decatur, Georgia

    c Yerkes National Primate Research Center, Emory Vaccine Center, Emory University, Atlanta, Georgia

    d Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia

    e Department of Chemistry, Emory University School of Medicine, Atlanta, Georgia

    f Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia

    Available online 3 April 2010.

    Objectives

    To develop a serum-based assay to detect neutralizing antibodies to the xenotropic murine leukemia virus-related virus (XMRV) retrovirus and to use this assay with polymerase chain reaction and fluorescence in situ hybridization to identify patients with prostate cancer previously exposed to XMRV infection and those who carry XMRV viral sequences in their prostate.

    Methods

    Patients who had undergone radical prostatectomy were enrolled, and biologic specimens were obtained at surgery. The patients were genotyped for the R462Q RNASEL variant using a TaqMan genotyping assay on DNA from the peripheral blood. A serum assay that detects XMRV neutralizing antibodies was developed and used to determine which patients had serologic evidence of previous infection with XMRV virus. Some of these patients were also tested for the presence of XMRV nucleotide sequences in their prostate using polymerase chain reaction and fluorescence in situ hybridization analysis.

    Results

    At a serum dilution of 1:150, our assay detected 11 (27.5%) of 40 patients with XMRV neutralizing antibodies, including 8 (40%) of 20 with the RNASEL genotype QQ and 3 (15%) of 20 with either the RQ or RR genotype. These results were in complete concordance with 2 other assays (polymerase chain reaction and fluorescence in situ hybridization), which were designed to detect XMRV infection.

    Conclusions

    XMRV infects some patients with prostate cancer. Neutralizing antibodies against XMRV correlated with 2 independent methods of detecting the virus in the prostate.
    The antibody response suggests that with clinical serologic assay development, it might be possible to screen patients for XMRV infection. The cases presented in the present report provided biologic samples that can be used for the development of a clinically relevant assay.

    This work was supported in part by the Research Scholar Award to Hinh Ly by the American Cancer Society (grant Reprint requests: John A. Petros, M.D., Department of Urology, Emory University School of Medicine, 1365 Clifton Road, Building B, Atlanta, GA 30322
    Urology Volume 75, Issue 4, April 2010, Pages 755-761
     
  2. Koan

    Koan Be the change.

    Messages:
    2,598
    Likes:
    55
    Thank you much, If!
     
  3. George

    George Guest

    I'd like to compare the two neutralizing assays, The one used in the Groom/Kerr paper and this one. Also, I wonder when the test is going to be available to the public?? Should we flood Emory University with requests for access to the test?? (big grins)

    So are we all sitting around lapping up . . . I mean drinking our coffee this morning checkin' the web? (I'm working on my table manners so I can sit with the big dogs, I mean people some day. Grin)
     
  4. Kati

    Kati Patient in training

    Messages:
    2,070
    Likes:
    1,604
    It gets better and better... What a great Easter Week end!!!
     
  5. jimbob

    jimbob ME/CFS84-XMRV+

    Messages:
    321
    Likes:
    9
    myrtle beach, s.c.
    holy cow, what a monday after a tough weekend for me. two major stories!!!!!!!!!! hopefully this will get things moving quicker, as I am sooooo very impatient!
     
  6. Gerwyn

    Gerwyn Guest

    PREVIOUSLY infected .The game is well and truly afoot
     
  7. George

    George Guest

    Yeah, so when do you get tested Gerwyn?
     
  8. Gerwyn

    Gerwyn Guest

    next tuesday

    note patients who currently have DNA and those who by implication dont have a look at the methodology!

    A serum assay that detects XMRV neutralizing antibodies was developed and used to determine which patients had serologic evidence of previous infection with XMRV virus.
     
  9. usedtobeperkytina

    usedtobeperkytina Senior Member

    Messages:
    1,384
    Likes:
    186
    Clay, Alabama
    Someone explain to me how seeing it in 11 of 40 who have the virus means it is a good assay.

    Is my brain just not computing again?

    Tina
     
  10. cfs since 1998

    cfs since 1998 *****

    Messages:
    577
    Likes:
    4
    "At a serum dilution of 1:150, our assay detected 11 (27.5%) of 40 patients with XMRV neutralizing antibodies"

    I think they mean that they detected it in 11 patients out of the 40 patients tested, not out of 40 XMRV known positives. But I can see how you would interpret it that way because of the order of the sentence.
     
  11. George

    George Guest

    The results they got were the same results as the PCR and FISH. In other words according to PCR and FISH only 11 of 40 were infected. So the serological test was in concordance with the other results, therefore we win we made the test first.

    I don't really get the "previous infection" wording part Gerwyn, I mean anybody infected was infected 'previously'. We're not talking about anybody who is being infected "currently" right???? So any infection is a 'previous infection' (head scratch)
     
  12. cfs since 1998

    cfs since 1998 *****

    Messages:
    577
    Likes:
    4
    It's because an antibody can't give you information on whether you are now infected, only that you were exposed at some point in time. When you are talking about a retrovirus though, it is usually assumed that an antibody = previous infection = current infection, since retroviruses can't be completely eliminated.
     
  13. George

    George Guest

    Yeah, that's what I was trying to say (grins) what CFS articulated so well! Thanks
     
  14. Gerwyn

    Gerwyn Guest


    the key word there is assumed they could not find it in the dna or in the blood so where is it
     
  15. Gerwyn

    Gerwyn Guest

    yes i know but it is an assumption and not fact i would love to see the entire methodology .XMRV is the first human gamma.When the term retroviruses is used it is genericised usually referring to known human retros. we really dont know very much about xmrv so we are assuming a hell of a lot.
     
  16. Gerwyn

    Gerwyn Guest

    sorry my bit is mixed with yours above

    We know about chronicity over a few months but the rest is anyones guess

    Chronic infection, though, appeared largely limited to CD4+ T cells in lymphoid organs -- spleen, lymph nodes, and GI tract -- as well as in reproductive organs, including prostate, testes, ovaries, vagina, and cervix.
     
  17. citybug

    citybug Senior Member

    Messages:
    522
    Likes:
    36
    NY
    They don't expect it to be a high rate in prostate cancer. They think it is a subset. I think this is higher percentage than earlier study of prostate cancer.

    The patients were genotyped for the R462Q RNASEL variant using a TaqMan genotyping assay on DNA from the peripheral blood. A serum assay that detects XMRV neutralizing antibodies was developed and used to determine which patients had serologic evidence of previous infection with XMRV virus. Some of these patients were also tested for the presence of XMRV nucleotide sequences in their prostate using polymerase chain reaction and fluorescence in situ hybridization analysis.

    Does anyone know if this is part of the CFS type XMRV? Don't trust my ability to check Science paper. Is this an antibody test for CFS XMRV verified by another lab? WPI probably knew this was coming out.
     

See more popular forum discussions.

Share This Page